Loading stock…

Monte Rosa Therapeutics, Inc. (GLUE) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Monte Rosa Therapeutics, Inc.

GLUEMarket cap $0.87BPrice $10.2

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops small-molecule drugs that hijack the body's own protein-recycling system to destroy disease-causing proteins once thought "undruggable." Its molecular glue platform targets cancer and immune disorders by degrading, not just blocking, harmful proteins.

In Bastion Portfolios?

52W Return+1%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)na–

Revenue Forecast

Rev CAGR (1y)-57%1

Rev CAGR (3y)-49%1

Rev CAGR (5y)-9%1

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+2Loss1

EPS Growth Y+3Loss1

Quality

Margins

EBIT Margin-633%1

Net Income Margin-561%1

Free Cash Flow Margin-112%1

Debt

Net Debt/EBITDAna–

Efficiency

ROE-43%1

ROA-31%1

Earnings Stabilityna–

GEAR+VERY WEAK1

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)na–

P/BV1.87

EV Multiples

EV/EBITDA Fwdna–

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield-3.7%2

Dividend Yieldna–

Momentum

Short term

1 month return-29%1

3 month return-58%1

YTD return-35%1

Mid term

Price vs 52wHigh39%1

1 year return+32%8

Long term

3 year return+101%8

5 year return-43%2

Risk Shield

Price Risk

Beta1.42

Volatility82%1

Free Cash Flow

Free Cash Flow Margin-112%1

Free Cash Flow Yield-3.7%2

Quality

ROCE-38%1

Earnings Stabilityna–

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

GLUEMonte Rosa Therapeutics

Revenue FY25$124M

GROWTH RATING↗

VERY WEAK2 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGRna–

Revenue, next 1Y-57%1

Revenue, next 3Y, CAGR-49%1

Revenue, next 5Y, CAGR-9%1

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

None flagged.

WEAKNESSES

Growth is the weak spot here, trailing 98% of companies worldwide.

Revenue is set to shrink 49%/yr over the next 3 years, behind most of the market.1/10

Revenue held flat over the last 3 years, but it is set to shrink 49%/yr from here.

Over five years revenue is set to shrink 9%/yr, behind 90% of companies worldwide.1/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business heading into decline. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK15 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-29%1

3-month return-58%1

YTD return-35%1

MID & LONG-TERM▾SCORE

% of 52-week high39%1

1-year return+32%8

3-year return+101%8

5-year return-43%2

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Average long-term results. Multi-year returns are middling (+101% over three years and -43% over five), roughly average for the market.

It's up 32% over the past year, but 61% below its 52-week high. That is right in line with the market.

WEAKNESSES

The stock is underperforming over the past month (-29%), over three months (-58%) and so far this year (-35%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the stock is underperforming over the past month, over three months and so far this year.

04Value

Are you paying a fair price for it?

Stop guessing on Monte Rosa Therapeutics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

GLUEMonte Rosa Therapeutics

Revenue FY25$124M

GROWTH RATING↗

VERY WEAK2 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGRna–

Revenue, next 1Y-57%1

Revenue, next 3Y, CAGR-49%1

Revenue, next 5Y, CAGR-9%1

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

None flagged.

WEAKNESSES

Growth is the weak spot here, trailing 98% of companies worldwide.

Revenue is set to shrink 49%/yr over the next 3 years, behind most of the market.1/10

Revenue held flat over the last 3 years, but it is set to shrink 49%/yr from here.

Over five years revenue is set to shrink 9%/yr, behind 90% of companies worldwide.1/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business heading into decline. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK15 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-29%1

3-month return-58%1

YTD return-35%1

MID & LONG-TERM▾SCORE

% of 52-week high39%1

1-year return+32%8

3-year return+101%8

5-year return-43%2

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Average long-term results. Multi-year returns are middling (+101% over three years and -43% over five), roughly average for the market.

It's up 32% over the past year, but 61% below its 52-week high. That is right in line with the market.

WEAKNESSES

The stock is underperforming over the past month (-29%), over three months (-58%) and so far this year (-35%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Monte Rosa Therapeutics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community